BROWNSTEIN HYATT FARBER SCHRECK, LLP for AMGEN USA INC.
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Medicare Part D; Medicare Part B; S. 1416 - Affordable Prescriptions for Patients Act of 2019; H.R.3 - Lower Drug Costs Now Act of 2019; H.R. 2693 - Increasing Access to Osteoporosis Testing for Medicare Beneficiaries Act of 2019; Issues related to patient access
| Lobbyist | Covered position, as disclosed |
|---|---|
| LAURA JOHNSON BOLLIER | — |
| NADEAM ELSHAMI | — |
| ELIZABETH ANNE MAIER | — |
| ALFRED MOTTUR | — |
| JEROME MURRAY | — |
Medicare/Medicaid MMM
Medicare Part D; Medicare Part B; S. 1416 - Affordable Prescriptions for Patients Act of 2019; H.R.3 - Lower Drug Costs Now Act of 2019 H.R. 2693 - Increasing Access to Osteoporosis Testing for Medicare Beneficiaries Act of 2019, Issues related to patient access
| Lobbyist | Covered position, as disclosed |
|---|---|
| EMILY FELDER | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.